Microba Life Sciences Limited Stock

Equities

MAP

AU0000209868

Healthcare Facilities & Services

Market Closed - Australian S.E. 01:53:18 2024-04-26 am EDT 5-day change 1st Jan Change
0.18 AUD +12.50% Intraday chart for Microba Life Sciences Limited -2.70% 0.00%
Sales 2024 * 11.81M 7.71M Sales 2025 * 17.97M 11.74M Capitalization 80.61M 52.66M
Net income 2024 * -17M -11.1M Net income 2025 * -16M -10.45M EV / Sales 2024 * 5.09 x
Net cash position 2024 * 20.45M 13.36M Net cash position 2025 * 17.07M 11.15M EV / Sales 2025 * 3.54 x
P/E ratio 2024 *
-4.62 x
P/E ratio 2025 *
-4.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 57.75%
More Fundamentals * Assessed data
Dynamic Chart
Microba's Revenue Climbs 297% in Fiscal Q3 MT
Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% MT
2,700,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024. CI
48,031,314 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024. CI
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data MT
Microba Life Sciences Rise 9% Following Launch of MetaPanel Test With Sonic Healthcare MT
Microba Life Sciences Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
8,250,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
54,500,297 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 27-JAN-2024. CI
Weak Oil Prices, China's Property Woes Hold Down Australian Shares MT
Microba Life Sciences Validates Safety, Tolerability of Inflammatory Bowel Disease Therapy in Phase One Trial MT
Microba Life Sciences Completes Acquisition of UK Microbiome Testing Company; Shares Slide 5% MT
Microba Life Sciences Limited completed the acquisition of Invivo Clinical Limited. CI
Microba Life Sciences Signs Research Agreement with IFF Subsidiary to Develop Allergy Treatments MT
Microba Life Sciences' Domestica, International Personal Testing Revenue Rises in Fiscal Q1 MT
More news
1 day+12.50%
1 week-2.70%
Current month-14.29%
1 month-16.28%
3 months+5.88%
6 months-21.74%
More quotes
1 week
0.16
Extreme 0.16
0.19
1 month
0.16
Extreme 0.16
0.21
Current year
0.15
Extreme 0.15
0.22
1 year
0.15
Extreme 0.15
0.45
3 years
0.14
Extreme 0.135
0.45
5 years
0.14
Extreme 0.135
0.45
10 years
0.14
Extreme 0.135
0.45
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 61 21-03-17
Director/Board Member - 22-09-07
Director/Board Member 61 -
More insiders
Date Price Change Volume
24-04-26 0.18 +12.50% 344,355
24-04-24 0.16 -5.88% 245,709
24-04-23 0.17 0.00% 478,630
24-04-22 0.17 -8.11% 265,958
24-04-19 0.185 +2.78% 73,995

Delayed Quote Australian S.E., April 26, 2024 at 01:53 am EDT

More quotes
Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. It also offers a product portfolio of gastrointestinal, vaginal, oral, and urinary microbiome testing, together with a targeted set of evidence-based formulations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.18 AUD
Average target price
0.38 AUD
Spread / Average Target
+111.11%
Consensus

Quarterly revenue - Rate of surprise